Skip to content

Study · Randomized controlled trial · n = 3,188 · 2015

8 results

Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme.

Raccah D, Miossec P, Esposito V, Niemoeller E, Cho M, Gerich J

Diabetes/metabolism research and reviews16 Sept 2014Cited by 35 (Europe PMC)

PMID25115916 (opens in a new tab)DOI10.1002/dmrr.2588 (opens in a new tab)PepBankPUB-25115916
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, lixisenatide significantly reduced HbA1c versus placebo across all age groups.

    In plain wordsIn patients with diabetes, lixisenatide reduced HbA1c compared with placebo in all age groups.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c by age group
    Study

    n = 3,188

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 µg once daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In the pooled analysis, lixisenatide 20 µg once daily provided significant reductions in HbA1c versus placebo for all age groups.
  2. 02HumanRandomized controlled trialSafety outcome

    In patients with type 2 diabetes, symptomatic hypoglycaemia incidence was generally comparable between lixisenatide and placebo.

    In plain wordsIn patients with diabetes, symptomatic hypoglycaemia rates were generally comparable between lixisenatide and placebo.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedSymptomatic hypoglycaemia
    Study

    n = 3,188

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    20 µg once daily · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The incidence of symptomatic hypoglycaemia was generally comparable between lixisenatide-treated and placebo-treated patients.
  3. 03HumanObservational studySafety outcome

    In the pooled diabetes analysis, treatment-emergent adverse event incidence was similar across age groups (69-73%).

    In plain wordsIn the pooled diabetes analysis, adverse event rates were similar across age groups.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedTreatment-emergent adverse events by age
    Study

    n = 3,188

    Comparator
    Other age groups
    Outcome group
    Adverse events · Pharmacology
    Studied dose
    20 µg once daily · subcutaneousAs given in this study (human).

    Measurements

    Treatment-emergent adverse event incidence
    69 to 73%
    across all age groups

    Source sentences

    Summary
    There was a similar incidence of treatment-emergent adverse events across all age groups (range: 69-73%).
    1 context sentence
    Summary · context
    The pooled analysis included 3188 patients, including 2565 patients <65 years old and 623 patients ≥65 years old (including 79 patients ≥75 years old).
  4. 04HumanObservational studyPharmacokinetics

    In healthy subjects, mean lixisenatide exposure was ~30% higher in elderly than young subjects after 20 µg.

    In plain wordsIn healthy subjects, lixisenatide exposure was higher in elderly than young subjects.

    Peptide
    Lixisenatide
    Outcome
    IncreaseMean exposure by age
    Study

    n = 36

    Comparator
    Young healthy subjects
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Measurements

    Mean exposure, elderly vs young
    ≈ 30 % higher
    elderly vs young healthy subjects, single 20 µg dose

    Source sentences

    Summary
    Mean exposure with lixisenatide 20 µg was ~30% higher in elderly than in young subjects, and the terminal half-life was prolonged by ~1.6 times.
    1 context sentence
    Summary · context
    The pharmacokinetics study included 36 healthy subjects, including 18 elderly healthy subjects (≥65 years old) and 18 matched young healthy subjects (18-45 years old).
  5. 05HumanObservational studyPharmacokinetics

    In healthy subjects, lixisenatide terminal half-life was prolonged by ~1.6 times in elderly versus young subjects.

    In plain wordsIn healthy subjects, lixisenatide remained in the body longer in elderly than young subjects.

    Peptide
    Lixisenatide
    Outcome
    IncreaseTerminal half-life by age
    Study

    n = 36

    Comparator
    Young healthy subjects
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Measurements

    Terminal half-life ratio, elderly vs young
    ≈ 1.6 times
    elderly vs young healthy subjects, single 20 µg dose

    Source sentences

    Summary
    Mean exposure with lixisenatide 20 µg was ~30% higher in elderly than in young subjects, and the terminal half-life was prolonged by ~1.6 times.
    1 context sentence
    Summary · context
    The pharmacokinetics study included 36 healthy subjects, including 18 elderly healthy subjects (≥65 years old) and 18 matched young healthy subjects (18-45 years old).
  6. 06HumanObservational studyPharmacokinetics

    In healthy subjects, lixisenatide maximum concentration was comparable in elderly and young subjects.

    In plain wordsIn healthy subjects, lixisenatide maximum concentration was comparable in elderly and young subjects.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedMaximum concentration by age
    Study

    n = 36

    Comparator
    Young healthy subjects
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Maximum concentration (C(max)) and time to C(max) (t(max)) were comparable in both groups.
    1 context sentence
    Summary · context
    The pharmacokinetics study included 36 healthy subjects, including 18 elderly healthy subjects (≥65 years old) and 18 matched young healthy subjects (18-45 years old).
  7. 07HumanObservational studyPharmacokinetics

    In healthy subjects, lixisenatide time to maximum concentration was comparable in elderly and young subjects.

    In plain wordsIn healthy subjects, the time to maximum lixisenatide concentration was comparable in elderly and young subjects.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedTime to maximum concentration by age
    Study

    n = 36

    Comparator
    Young healthy subjects
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Maximum concentration (C(max)) and time to C(max) (t(max)) were comparable in both groups.
    1 context sentence
    Summary · context
    The pharmacokinetics study included 36 healthy subjects, including 18 elderly healthy subjects (≥65 years old) and 18 matched young healthy subjects (18-45 years old).
  8. 08HumanObservational studySafety outcome

    In healthy subjects receiving lixisenatide, equal numbers of elderly and young subjects reported treatment-emergent adverse events, mostly gastrointestinal disorders.

    In plain wordsIn healthy subjects receiving lixisenatide, equal numbers of elderly and young subjects reported adverse events, mostly digestive disorders.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedTreatment-emergent adverse events after single dose
    Study

    n = 36

    Comparator
    Young healthy subjects
    Outcome group
    Adverse events · Pharmacology
    Studied dose
    20 µg · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Equal numbers of elderly and young subjects reported treatment-emergent adverse events, the majority of which were gastrointestinal disorders.
    1 context sentence
    Summary · context
    The pharmacokinetics study included 36 healthy subjects, including 18 elderly healthy subjects (≥65 years old) and 18 matched young healthy subjects (18-45 years old).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.